Xu Y, et al. - Authors investigated the data to assess the DHX15 expression in castration-resistant prostate cancer (CRPC) specimens and the impact of DHX15 on prostate cancer cells' response to DHT stimulation. They noticed an upregulated expression level of DHX15 in human CRPC as compared to hormone-naive prostate cancer specimens. They also found a drop in AR sensitivity to low DHT concentrations in C4-2 cells due to DHX15 knockdown. The enzalutamide treatment in C4-2 cells was sensitized by inactivation of DHX15. Interaction of DHX1 5 with AR through its N terminal domain was indicated via deletion mutagenesis.